CoChat

A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes

Edelman, Steve, Garg, Satish, Frias, Juan, Maggs, David, Wang, Yan, Zhang, Bei, Strobel, Susan, Lutz, Karen, Kolterman, Orville · 2006 · Diabetes Care

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE—To assess safety, efficacy, and tolerability of pramlintide dose escalation with proactive mealtime insulin reduction, followed by insulin optimization, in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS—This 29-week, double-blind, placebo-controlled study randomized 296 patients to pramlintide or placebo as an adjunct to insulin. During initiation, pramlintide was escalated from 15 to 60 μg/meal (15-μg increments) with recommended reductions (30–50%) in mealtime insulin. Insulin was subsequently adjusted to optimize glycemic control. End points included safety and change in HbA1c (A1C), postprandial glucose, insulin, weight, and tolerability. RESULTS—Baseline A1C was 8.1% for both groups and at week 29 had decreased comparably (pramlintide −0.5% [95% CI −0.61 to −0.33]; placebo −0.5% [−0.63 to −0.35]). Pramlintide treatment significantly reduced postprandial glucose excursions (incremental area under the curve [AUC]0–3h: pramlintide −175 ± 40, placebo −64 ± 38 mg · h−1 · dl−1; P < 0.0005) and weight (pramlintide −1.3 ± 0.30, placebo +1.2 ± 0.30 kg; P < 0.0001). At week 29, insulin dose decreased by 28 and 4% in pramlintide- and placebo-treated groups, respectively. Nausea, reported by 63 and 36% of patients in pramlintide and placebo groups (P < 0.01), respectively, was predominately mild to moderate in intensity. Severe hypoglycemia rates were low in both groups (pramlintide 0.57 ± 0.09, placebo 0.30 ± 0.06 event rate/patient-year; P < 0.05), with increased rates observed in patients remaining at 30 μg pramlintide. CONCLUSIONS—Pramlintide dose escalation with reduced mealtime insulin was effective during therapy initiation in patients with type 1 diabetes. While both groups experienced equivalent A1C reductions relative to placebo, pramlintide-treated patients experienced reductions in postprandial glucose excursions and weight, not achievable with insulin therapy alone.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc06-0042

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 174

Metadata

Authors
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O.
Affiliations
  • Division of Diabetes/Metabolism, San Diego VA Medical Center, San Diego, California
  • Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado
  • Amylin Pharmaceuticals, San Diego, California
Venue
Diabetes Care
Published
2006-10-01
Volume
29
Issue
10
Pages
2189-2195
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2126969411
Cited by
166
References
25
Citations by year
2026: 3 · 2025: 7 · 2024: 8 · 2023: 2 · 2022: 5 · 2021: 6 · 2020: 10 · 2019: 10 · 2018: 15 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 5 · 2013: 5 · 2012: 6
FWCI
9.06
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 1 diabetes, intensive insulin therapy, glycemic control, HbA1c, postprandial blood glucose, weight loss, nausea, hypoglycemia, GLP-1 receptor agonists, dose escalation, weight gain, weight loss maintenance
MeSH terms
Adult, Amyloid, Blood Glucose, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Eating, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.